GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 17 09:18

Express News | Haisco Pharmaceutical Group: HSK44459 tablets have received approval for two new indications for clinical trials.

BreakingsMar 12 18:17

Express News | Huayuan Securities initiates a "Buy" rating for Sichuan Kelun Pharmaceutical, as Innovative Drugs are about to enter the commercialization phase.

BreakingsMar 7 14:14

Haisco Pharmaceutical Group Clarifies No Financial Assistance in Share Issuance

MT NewswiresMar 3 16:22

Haisco Pharmaceutical Group (002653.SZ): Plans to raise no more than 1.365 billion yuan through a private placement to invest in new drug research and development projects, among others.

On February 27th, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced plans to issue A-shares to specific objects for the year 2025, with the number of shares issued not exceeding 70,000,000 shares (inclusive), which, based on the company's total share capital, is not more than 30% of the total share capital before this issuance. The total amount raised from the issuance of shares to specific objects will not exceed 1.365 billion yuan (inclusive), with a net amount of approximately 0.965 billion yuan intended for investment in new drug research and development projects, and 0.4 billion yuan for replenishing working capital.

Gelonghui FinanceFeb 27 19:50

Express News | Huayuan Securities: Maintaining Xinlitai's “buy” rating, the downstream chronic disease market has broad potential

BreakingsFeb 27 16:53